Cargando…

Serological Responses after a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis

The humoral immune response and safety of the fourth dose of the coronavirus disease 2019 (COVID-19) vaccine in solid organ transplant (SOT) recipients need to be fully elucidated. We conducted a systematic review and meta-analysis to assess the efficacy and safety associated with this additional do...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Yameng, Wu, Hongxiao, Jiang, Zhouling, Liu, Kehang, Xue, Xiaoyu, Zhang, Wei, Chen, Zhihai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385971/
https://www.ncbi.nlm.nih.gov/pubmed/37514946
http://dx.doi.org/10.3390/vaccines11071130
_version_ 1785081544774254592
author Mu, Yameng
Wu, Hongxiao
Jiang, Zhouling
Liu, Kehang
Xue, Xiaoyu
Zhang, Wei
Chen, Zhihai
author_facet Mu, Yameng
Wu, Hongxiao
Jiang, Zhouling
Liu, Kehang
Xue, Xiaoyu
Zhang, Wei
Chen, Zhihai
author_sort Mu, Yameng
collection PubMed
description The humoral immune response and safety of the fourth dose of the coronavirus disease 2019 (COVID-19) vaccine in solid organ transplant (SOT) recipients need to be fully elucidated. We conducted a systematic review and meta-analysis to assess the efficacy and safety associated with this additional dose of the COVID-19 vaccine in the SOT recipients. A comprehensive search was conducted to identify studies on SOT patients without prior natural SARS-CoV-2 infection who received the fourth dose of the COVID-19 vaccine. Serological antibody responses following vaccination were synthesized by a meta-analysis of proportions. The proportions for each outcome were integrated by using a random-effects model. Approximately 56–92% of the SOT patients developed a humoral immune response, and the pooled seroprevalence rate was 75% (95% confidence interval [CI], 62–82%) after administering the third vaccine dose. Following the fourth dose of vaccination, approximately 76–95% of the patients developed a humoral immune response. The pooled seroprevalence rate after the fourth dose was 85% (95% CI, 79–91%). Of the patients who initially tested seronegative after the second dose, approximately 22–76% of patients subsequently became seropositive after the third dose. The pooled seroconversion rate for the third dose was 47% (95% CI, 31–64%). Among the patients who were seronegative after the third dose, approximately 25–76% turned seropositive after the fourth dose. The pooled seroconversion rate after the fourth dose was 51% (95% CI, 40–63%). Safety data were reported in three studies, demonstrating that adverse effects following the fourth dose were generally mild, and patients with these adverse effects did not require hospitalization. No transplant rejection or serious adverse events were observed. A fourth dose of the COVID-19 vaccine in SOT recipients was associated with an improved humoral immune response, and the vaccine was considered relatively safe.
format Online
Article
Text
id pubmed-10385971
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103859712023-07-30 Serological Responses after a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis Mu, Yameng Wu, Hongxiao Jiang, Zhouling Liu, Kehang Xue, Xiaoyu Zhang, Wei Chen, Zhihai Vaccines (Basel) Systematic Review The humoral immune response and safety of the fourth dose of the coronavirus disease 2019 (COVID-19) vaccine in solid organ transplant (SOT) recipients need to be fully elucidated. We conducted a systematic review and meta-analysis to assess the efficacy and safety associated with this additional dose of the COVID-19 vaccine in the SOT recipients. A comprehensive search was conducted to identify studies on SOT patients without prior natural SARS-CoV-2 infection who received the fourth dose of the COVID-19 vaccine. Serological antibody responses following vaccination were synthesized by a meta-analysis of proportions. The proportions for each outcome were integrated by using a random-effects model. Approximately 56–92% of the SOT patients developed a humoral immune response, and the pooled seroprevalence rate was 75% (95% confidence interval [CI], 62–82%) after administering the third vaccine dose. Following the fourth dose of vaccination, approximately 76–95% of the patients developed a humoral immune response. The pooled seroprevalence rate after the fourth dose was 85% (95% CI, 79–91%). Of the patients who initially tested seronegative after the second dose, approximately 22–76% of patients subsequently became seropositive after the third dose. The pooled seroconversion rate for the third dose was 47% (95% CI, 31–64%). Among the patients who were seronegative after the third dose, approximately 25–76% turned seropositive after the fourth dose. The pooled seroconversion rate after the fourth dose was 51% (95% CI, 40–63%). Safety data were reported in three studies, demonstrating that adverse effects following the fourth dose were generally mild, and patients with these adverse effects did not require hospitalization. No transplant rejection or serious adverse events were observed. A fourth dose of the COVID-19 vaccine in SOT recipients was associated with an improved humoral immune response, and the vaccine was considered relatively safe. MDPI 2023-06-21 /pmc/articles/PMC10385971/ /pubmed/37514946 http://dx.doi.org/10.3390/vaccines11071130 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Mu, Yameng
Wu, Hongxiao
Jiang, Zhouling
Liu, Kehang
Xue, Xiaoyu
Zhang, Wei
Chen, Zhihai
Serological Responses after a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis
title Serological Responses after a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis
title_full Serological Responses after a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis
title_fullStr Serological Responses after a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis
title_full_unstemmed Serological Responses after a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis
title_short Serological Responses after a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis
title_sort serological responses after a fourth dose of sars-cov-2 vaccine in solid organ transplant recipients: a systematic review and meta-analysis
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385971/
https://www.ncbi.nlm.nih.gov/pubmed/37514946
http://dx.doi.org/10.3390/vaccines11071130
work_keys_str_mv AT muyameng serologicalresponsesafterafourthdoseofsarscov2vaccineinsolidorgantransplantrecipientsasystematicreviewandmetaanalysis
AT wuhongxiao serologicalresponsesafterafourthdoseofsarscov2vaccineinsolidorgantransplantrecipientsasystematicreviewandmetaanalysis
AT jiangzhouling serologicalresponsesafterafourthdoseofsarscov2vaccineinsolidorgantransplantrecipientsasystematicreviewandmetaanalysis
AT liukehang serologicalresponsesafterafourthdoseofsarscov2vaccineinsolidorgantransplantrecipientsasystematicreviewandmetaanalysis
AT xuexiaoyu serologicalresponsesafterafourthdoseofsarscov2vaccineinsolidorgantransplantrecipientsasystematicreviewandmetaanalysis
AT zhangwei serologicalresponsesafterafourthdoseofsarscov2vaccineinsolidorgantransplantrecipientsasystematicreviewandmetaanalysis
AT chenzhihai serologicalresponsesafterafourthdoseofsarscov2vaccineinsolidorgantransplantrecipientsasystematicreviewandmetaanalysis